Oncogenic KRAS mutations result in a hyperactivated protein, and mutant KRAS is a key driver in many cancers, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and lung adenocarcinoma (LUAD)4. This evidence concerns the gene KRAS and cancer.